-
| CurrencyCode | USD |
|---|---|
| ISIN | None |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
| Market Cap | 980 |
|---|---|
| PE Ratio | None |
| Target Price | 21 |
| Beta | 3.08 |
| Dividend Yield | 0.0% |
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California. On June 1, 2022, Zosano Pharma Corporation filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on November 22, 2022.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ZSANQ using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025